Thursday, September 13, 2018
Stryker price target raised to $200 from $190 at JPMorgan
JPMorgan analyst Robbie Marcus raised his price target for Stryker to $200 saying the company is poised to post “top-tier” growth in the second half of 2018 and beyond. The analyst sees Stryker as one of the highest quality names in the MedTech space and a core MedTech holding. He believes current share levels provide an attractive entry point and reiterates an Overweight rating on the name.
https://thefly.com/landingPageNews.php?id=2789783
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.